Annual rates of change in pre-vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD

Respiratory Medicine

Volumn 107, Issue 12, 2013, Pages 1904-1911

  Tashkin, Donald P ^a   Li, Ning ^a   Halpin, David ^b   Kleerup, Eric ^a   Decramer, Marc ^c   Celli, Bartolome ^d   Elashoff, Robert ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

COPD; Post bronchodilator; Slope of FEV1 decline; UPLIFT

Indexed keywords

BRONCHODILATING AGENT; SALBUTAMOL; TIOTROPIUM BROMIDE;

ADULT; AIRWAY OBSTRUCTION; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INHALER; LUNG FUNCTION; MALE; MEASUREMENT; PRIORITY JOURNAL;

COPD; POST-BRONCHODILATOR; SLOPE OF FEV(1) DECLINE; UPLIFT;

ADMINISTRATION, INHALATION; ALBUTEROL; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; IPRATROPIUM; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; VITAL CAPACITY;

EID: 84890316324     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2013.08.001     Document Type: Article

References (24)

1. 1 over 5 years in mild to moderate COPD: results of the Lung Health Study Respir Res 13 2012 70
2. 1. The Lung Health Study JAMA 272 1994 1497 1505
3. P.D. Scanlon, J.E. Connett, L.A. Waller for the Lung Health Study Research Group Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: the lung health study Am J Respir Crit Care Med 161 2000 381 390
4. R.A. Pauwels, C.-G. Lofdahl, and L.A. Laitinen Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking N Engl J Med 340 1999 1948 1953
5. P.S. Burge, P.M.A. Calverley, and P.W. Jones Randomised, double-blind, placebo-controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial BMJ 320 2000 1297 1303
6. J. Vestbo, T. Sorensen, and P. Lange Long-term effect of inhaled budesonide im mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial Lancet 353 1999 1819 1823
7. The Lung Health Study Research Group Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease N Engl J Med 343 2000 1902 1909
8. M. Decramer, M. Rutten-van Molken, and P.N.R. Dekhuijzen Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial Lancet 365 2005 1552 1560
9. D.P. Tashkin, B. Celli, S. Senn for the UPLIFT study investigators A 4-year trial of tiotropium in chronic obstructive pulmonary disease N Engl J Med 359 2008 1543 1554
10. B.R. Celli, N.E. Thomas, and J.A. Anderson Effect of pharmacotherapy on rate of decline in lung function in chronic obstructive pulmonary disease. Results from the TORCH study Am J Respir Crit Care Med 178 2008 332 338
11. D.P. Tashkin, B. Celli, and M. Decramer Bronchodilator responsiveness in patients with COPD Eur Respir J 31 2008 742 750
12. B. Celli, D.P. Tashkin, and S.I. Rennard Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in patients with COPD Respir Med 105 2011 1176 1188
13. S. Haney, and R.J. Hancox Rapid onset of tolerance to beta-agonist bronchodilation Respir Med 99 2005 566 571
14. 2 adrenergic agents Chest 73 1978 949 957
15. 1 decline over time in COPD and its implications Curr Opin Pulm Med 19 2013 116 124
16. P.M. Calverley, A. Lee, and L. Towse Effect on tiotropium on circadian variation in airflow limitation in chronic obstructive pulmonary disease Thorax 58 2003 855 860
17. M. Nisar, J.E. Earis, and M.G. Pearson Acute bronchodilator trials in chronic obstructive pulmonary disease Am Rev Respir Dis 146 1992 555 559
18. P.M. Dorinsky, C. Reisner, and G.T. Ferguson The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD Chest 115 1999 966 971
19. P.M. Calverley, P.S. Burge, and S. Spencer Bronchodilator reversibility testing in chronic obstructive pulmonary disease Thorax 58 2003 659 664
20. M. Decramer, B. Celli, S. Kesten for the UPLIFT investigators Effects of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomized control trial Lancet 374 2009 1171 1178
21. T. Troosters, B. Celli, T. Lystig on behalf of the UPLIFT investigators Tiotropium as a first maintenance drug in COPD: a secondary analysis of the UPLIFT Eur Respir J 36 2010 65 73
22. A.H. Morice, B. Celli, and S. Kesten COPD in young patients: a pre-sepcified analysis of the four-year trial of tiotropium (UPLIFT) Respir Med 104 2010 1659 1667
23. ® experience Respir Med 107 9 2013 1409 1416
24. R.M. Elashoff, G. Li, and N. Li A joint model for longitudinal measurements and survival data in the presence of multiple failure types Biometrics 64 2008 762 771